Suppr超能文献

压碎的延迟释放泊沙康唑片治疗鼻-眶-脑毛霉病的疗效。

Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis.

机构信息

Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.

Department of Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.

出版信息

Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0108522. doi: 10.1128/aac.01085-22. Epub 2022 Nov 15.

DOI:10.1128/aac.01085-22
PMID:36377934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9765161/
Abstract

A significant proportion of patients with Rhino-orbito-cerebral mucormycosis (ROCM) develop oroantral fistulas. Due to the unclear efficacy of crushed delayed-release posaconazole tablets (DRPT) via nasogastric tube in this group of patients, clinicians often use inferior alternatives like posaconazole suspension. In this prospective study, we report good plasma concentrations (median, 2,639 ng/mL; interquartile range [IQR], 1,690 to 3,575 ng/mL; and range, 1,004 to 4,835ng/mL) and complete cure and survival at 3 and 6 months in 19 such patients.

摘要

相当比例的鼻-眶-脑毛霉菌病（ROCM）患者会发展成口鼻瘘。由于经鼻胃管给予粉碎后的泊沙康唑延迟释放片（DRPT）在这组患者中的疗效不明确，临床医生通常会选择泊沙康唑混悬剂等替代药物。在这项前瞻性研究中，我们报告了 19 例此类患者的良好血浆浓度（中位数 2639ng/ml；四分位距 [IQR] 1690 至 3575ng/ml；范围 1004 至 4835ng/ml），并且在 3 个月和 6 个月时，所有患者均完全治愈并存活。

相似文献

1
Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0108522. doi: 10.1128/aac.01085-22. Epub 2022 Nov 15.
2
Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.
Mycoses. 2016 Dec;59(12):765-772. doi: 10.1111/myc.12529. Epub 2016 Jul 22.
3
Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study.
Clin Microbiol Infect. 2023 Oct;29(10):1298-1305. doi: 10.1016/j.cmi.2023.06.017. Epub 2023 Jun 20.
4
COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis.
Indian J Pharmacol. 2021 Nov-Dec;53(6):499-510. doi: 10.4103/ijp.ijp_839_21.
5
Survival in rhino-orbito-cerebral mucormycosis: An international, multicenter ID-IRI study.
Eur J Intern Med. 2022 Jun;100:56-61. doi: 10.1016/j.ejim.2022.03.008. Epub 2022 Mar 15.
6
Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis.
Br J Ophthalmol. 2019 Oct;103(10):1460-1465. doi: 10.1136/bjophthalmol-2018-312688. Epub 2018 Dec 4.
7
Rhino-Orbito-Cerebral Mucormycosis in Diabetic Disease Mucormycosis in Diabetic Disease.
J Craniofac Surg. 2020 Jun;31(4):e321-e324. doi: 10.1097/SCS.0000000000006191.
8
Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.
Med Mycol. 2023 Jul 6;61(7). doi: 10.1093/mmy/myad067.
9
Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes - a tertiary care center experience.
J Mycol Med. 2022 May;32(2):101238. doi: 10.1016/j.mycmed.2021.101238. Epub 2021 Dec 25.
10
A case report on clinical features, diagnosis, and treatment of rhino-orbito-cerebral mucormycosis.
Immun Inflamm Dis. 2023 Nov;11(11):e1080. doi: 10.1002/iid3.1080.

本文引用的文献

1
Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules.
J Antimicrob Chemother. 2022 Apr 27;77(5):1417-1423. doi: 10.1093/jac/dkac035.
2
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1.
3
Pharmacokinetics and Pharmacodynamics of Posaconazole.
Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y.
4
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.
Lancet Infect Dis. 2019 Dec;19(12):e405-e421. doi: 10.1016/S1473-3099(19)30312-3. Epub 2019 Nov 5.
5
Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.
Clin Infect Dis. 2020 Jun 10;70(12):2593-2598. doi: 10.1093/cid/ciz741.
6
Serum Levels of Crushed Posaconazole Delayed-Release Tablets.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02688-18. Print 2019 May.
7
Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.
Mycoses. 2016 Dec;59(12):765-772. doi: 10.1111/myc.12529. Epub 2016 Jul 22.
8
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections.
Clin Pharmacol. 2015 Dec 23;8:1-8. doi: 10.2147/CPAA.S60933. eCollection 2016.
9
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5. doi: 10.1128/AAC.02448-13. Epub 2014 May 5.
10
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验